9 Intl Symposium - Functional Neuroreceptor Mapping of the Living Brain NRM 2012

描述(由申请人提供)：我们寻求NIMH以及NIDA、NIAAA、NINDS、NIA和NIBIB的支持，以主办于2012年8月9日至11日在马里兰州巴尔的摩举行的第九届活脑功能神经受体图谱国际研讨会(NRM12)。本次研讨会是学术界和制药行业的研究人员和医生两年一次的会议，他们的研究重点是开发非侵入性成像技术，如正电子发射断层扫描(PET)和单光子发射计算机断层扫描(SPECT)，以及其他分子成像方法，以从功能上表征和量化活脑中的神经递质(如5-羟色胺-2A、多巴胺-D2)和其他神经生物学过程(如淀粉样蛋白、神经炎症)。会议科学会议的总体目标是应用非侵入性神经成像方法来：1)提高对神经退行性疾病和精神疾病、成瘾障碍、衰老和心理过程的病理生理学的理解；2)开发改进的方法来量化体内的神经受体功能；3)有效地利用分子成像技术来加快中枢神经系统(CNS)药物的开发进程；4)将分子成像措施扩展到新的领域，如成像心理过程(如认知、应激)；以及5)开发多模式成像(如PET/fMRI)的方法和应用。会议的科学计划将集中在与NIH神经科学赞助的研究直接相关的基础和临床研究上。研讨会方案的主要组成部分将包括大约50个平台演讲和150个海报摘要演讲。该计划还将包括三次全体讲座，三次由4-5名专家领导的关键问题小组专题讨论，以及培训和网络活动。本次研讨会将利用一个真正国际化和多学科的研究人员和医生小组的广泛专业知识，他们在功能神经成像和相关领域工作，以确定和探索可能促进临床诊断和药物开发的翻译研究机会，并建立和促进小组之间的沟通、合作和联谊。初级调查员奖励计划将使受训人员能够参加会议并向高级同事介绍他们的工作。研讨会的一个关键成果将是计划和摘要出版物，这本书将提供给与会代表和NIH计划官员，并计划以.pdf电子文件的形式在会议结束后至少一年内发布在研讨会网站上，供全球传播。 公共卫生相关性：这是一项会议赠款，用于支持在北美和欧洲每两年轮流举行的第9届国际神经受体图谱会议。没有官方的协会，但这是一个由大约250-300名基础和翻译科学家组成的忠诚团体参加的一次非常有人数的会议，他们致力于神经受体图谱的各个方面(即，对脑神经受体和神经递质系统成像的放射性药物的PET和SPECT成像)。本次会议将继续推动该领域从放射化学到临床应用的最新发展，重点领域包括将认知神经科学(传统上是功能磁共振成像的一部分)与神经受体映射(传统上是药物和配体的成像以及药物开发的一部分)相结合的进展，以及神经变性中神经受体和淀粉样蛋白成像的进展。

DESCRIPTION (provided by applicant): We seek $50,000 in support from NIMH, and NIDA, NIAAA, NINDS, NIA, and NIBIB to host the 9th International Symposium on Functional Neuroreceptor Mapping of the Living Brain (NRM12) from August 9 - 11, 2012 in Baltimore, MD. This symposium is a biennial meeting of researchers and physicians in academia and the pharmaceutical industry whose research focuses on the development of non-invasive imaging techniques, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), and other molecular imaging methods to functionally characterize and quantify neurotransmitters (e.g., serotonin-2A, dopamine-D2) and other neurobiological processes (e.g., amyloid, neuroinflammation) in the living brain. The overarching goals of scientific sessions of the meeting are to apply noninvasive neuroimaging methods to: 1) improve the understanding of the pathophysiology of neurodegenerative diseases and psychiatric disorders, addictive disorders, and aging and psychological processes; 2) to develop improved methods of quantifying neuroreceptor function in vivo; 3) to effectively use molecular imaging techniques to accelerate the process of central nervous system (CNS) drug development; 4) to expand molecular imaging measures to new areas such as imaging psychological processes (e.g., cognition, stress); and 5) to develop methods and applications of multimodality imaging (e.g., PET/fMRI). The scientific program for the meeting will focus on basic and clinical research that is of direct relevance to NIH Neuroscience sponsored research. The main component of the symposium program will include approximately 50 platform presentations and 150 poster abstract presentations. The program will also include three plenary lectures, three panel thematic discussions of key issues led by 4-5 experts each, and training and networking events. This symposium will leverage the breadth of expertise of a truly international and multidisciplinary group of researchers and physicians, who work in the area of functional neuroimaging and related fields, to identify and explore translational research opportunities that may advance clinical diagnostics and drug development and to establish and foster communication, collaboration, and fellowship among the group. A junior investigator award program will enable trainees to attend the meeting and to present their work to senior colleagues. A key outcome of the symposium will be the program and abstract publication book, which will be made available to meeting delegates and NIH program officials and is planned as an electronic .pdf file to post on the symposium website for a minimum of 1 year after the conference for global dissemination. PUBLIC HEALTH RELEVANCE: This is a conference grant to support the 9th International Neuroreceptor Mapping Meeting that is held alternately in North America and Europe bi-annually. There is no official society, but this has been an extremely well attended meeting by a loyal group of about 250-300 basic and translational scientists who are dedicated to all aspects of neuroreceptor mapping (i.e., PET and SPECT imaging of radiopharmaceuticals that image brain neuroreceptor and neurotransmitter systems). This meeting will continue to promote the state of the art of this field from radiochemistry to clinical applications, and will feature focus areas including advances in integrating cognitive neuroscience (which is traditionally a part of fMRI) with neuroreceptor mapping (traditionally imaging of drugs and ligands and a part of drug development), as well as advances in neuroreceptor and amyloid imaging in neurodegeneration.